ロード中...
Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells
FDA approval of new therapies in 2011 has greatly expanded the treatment options for metastatic melanoma. Patients with V600 mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) positive metastatic melanoma are now treated with the RAF inhibitor, vemurafenib (Zelboraf) as a first line thera...
保存先:
主要な著者: | , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
e-Century Publishing Corporation
2012
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3512187/ https://ncbi.nlm.nih.gov/pubmed/23226618 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|